iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Algert Global LLC

Algert Global LLC decreased its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 72.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,512 shares of the company's stock after selling 186,627 shares during the period. Algert Global LLC owned about 0.19% of iTeos Therapeutics worth $534,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in shares of iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after acquiring an additional 1,601,477 shares during the period. Dimensional Fund Advisors LP lifted its position in iTeos Therapeutics by 15.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock valued at $9,293,000 after acquiring an additional 163,880 shares in the last quarter. Boxer Capital Management LLC purchased a new position in shares of iTeos Therapeutics during the fourth quarter valued at approximately $7,272,000. Renaissance Technologies LLC grew its stake in shares of iTeos Therapeutics by 56.1% in the 4th quarter. Renaissance Technologies LLC now owns 837,200 shares of the company's stock worth $6,430,000 after acquiring an additional 300,800 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of iTeos Therapeutics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 644,901 shares of the company's stock worth $4,954,000 after buying an additional 4,551 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Trading Down 3.2%

Shares of NASDAQ:ITOS traded down $0.25 on Wednesday, hitting $7.60. 3,752,459 shares of the company were exchanged, compared to its average volume of 523,525. The stock's 50 day moving average price is $6.56 and its 200 day moving average price is $7.43. The firm has a market capitalization of $290.88 million, a P/E ratio of -2.41 and a beta of 1.39. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. On average, equities analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ITOS has been the topic of several recent research reports. Wells Fargo & Company restated an "overweight" rating and set a $13.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price target for the company from $15.00 to $8.00 in a report on Tuesday. Piper Sandler restated an "overweight" rating and set a $12.00 price target (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday. HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday. Finally, Wedbush restated an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $17.86.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.